Erythromycin, a macrolide antibiotic with motilin receptor agonist activity, has also been utilized; however, its benefit in SSc-associated dysmotility appears limited, with some studies suggesting paradoxical inhibition of intestinal motility [3,22,23]. This evidence concerns the gene MLNR and systemic sclerosis.